IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.
09. September 2024 11:12 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
06. November 2023 07:30 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Nov. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that the Israel Innovation Authority (IIA) has approved a non-dilutive grant...
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
03. November 2023 16:30 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
31. Oktober 2023 09:00 ET
|
Scinai Immunotherapeutics Ltd.
Recently rebranded Scinai Immunotherapeutics shifted drug development focus from COVID-19 antibody to a novel antibody for the treatment of psoriasis and launched a CDMO business unitAdjusted terms...
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
31. Oktober 2023 08:23 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
30. Oktober 2023 07:00 ET
|
Scinai Immunotherapeutics Ltd.
Showcasing Scinai’s end-to-end cGMP Biologics CDMO services at booth 271 Pursuing partnerships for Scinai’s pipeline of novel VHH antibody-based therapies JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE)...
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
04. Oktober 2023 07:30 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that it will be showcasing its CDMO services at CPHI Barcelona, one of the...
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
15. September 2023 09:01 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
11. September 2023 07:30 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., announced today...